Background: Leukemias and lymphomas are malignant disorders that occur in the blood forming organs and lymphoid tissue respectively. They are classified to types and several subtypes such as acute or chronic, lymphocytic or myelocytic and T-cell or B-cell lymphocytic for leukemias and histologically into Hodgkin’s and Non-Hodgkin’s for lymphomas. Literatures do not contain many research work on magnesium in patients with these disorders, although this mineral is essential for many metabolic, enzymic, regulatory and immune reactions in the human body. Therefore, the present study was aimed to evaluate the level of magnesium in the sera of patients with different types of leukemia and lymphoma. Patients and Methods: Fifty five patients with leukemia and lymphoma and twenty five healthy controls were studied. The patients were attendants of Baghdad Teaching Hospital and Pediatric Teaching Hospital from September 2006 to January 2007. The diagnosis was confirmed by examination of both peripheral blood, lymph node biopsy and/or bone marrow examination. Patients were categorized according to French-American-British Criteria. Thirty five patients with ALL, one with CLL, six with AML, three with CML, three with HL and seven with NHL. Venous blood was collected from each patient or control person and sera were obtained by centrifugation. S[Mg] was measured by Atomic Absorption Flame Spectrophotometry.Results:The Mean ± SD of S[Mg] in mg/dl of all types of leukemic and lymphomatous patients was lower than the controls. There was a high statistically significant difference (P<0.01) in patients with ALL and significant difference (P<0.05) in patients with AML and NHL and non-significant difference (P>0.05) in patients with CML and HL, compared with the control. Total patients group showed high significant difference (P<0.01) compared with control group. The mean distribution of S[Mg] among total patients indicated decreased (58.2%), normal (38.2%) and increased (3.6%) levels.Conclusion:The present study disclosed the existence of normal to decreased level of S[Mg] in patients with leukemia and lymphoma suggesting an influence of many variable factors. Although the decreased S[Mg] was statistically significant, it was still within lower normal range.

Leukemia --- Lymphoma serum Magnesium

Background: Methoxy polyethylene glycol-Epoetin beta (M.PG.E-β) is a long-acting erythropoietin receptor activator treatment indicated for the treatment of patients with anemia associated with end stage renal disease (E.S.R.D). It is the first approved chemically modified erythropoiesis-stimulating agent (E.S.A). Hypermagnesemia is one of the common complications accompanied with E.S.R.D patients submitted to hemodialysis. It progresses early in the course of the disease and increases its rate with the declination in renal efficacy.Objective: This study targeted to determine the influence of M.PG.E-β therapy on serum Mg+2 levels in patients with E.S.R.D.Patients and Methods: In this study , seventy patients with E.S.R.D on hemodialysis receiving M.PG.E-β and twenty healthy subjects without medical illnesses were included in this case-control cross sectional study. Results: Patients had significantly higher serum Mg+2 level at the baseline (p<0.01) compared to the healthy control group because of loss of renal function in these patients. M.PG.E-β dose was then given three months after the baseline dose and showed a significant decline in serum Mg+2 levels (p<0.05) in patients with E.S.R.D during the study.Conclusion: It can be concluded that relative elevation of serum Mg+2 was linked with E.S.R.D patients and the administration of M.PG.E-β usually leads to a significant subside in its levels.

خلفية الدراسة: يعتبر علاج ميثوكسي بولي اثيلين غليكول ايبوتين-بيتا علاجا منشطا لمستقبل الايرثروبويتين مديدة المفعول و يوصى باستعماله في علاج المرضى الذين يعانون من فقر الدم المصاحب للداء الكلوي بمراحله الاخيرة. و يعتبر هذا العلاج اول عامل مقبول و معدل كيميائيا يستخدم كمحفز لعملية تكوين الكريات الحمر. ان زيادة المغنيسيوم في الدم هو احد المضاعفات الشائعة التي تصاحب مرضى الداء الكلوي بمراحله الاخيرة من الذين يخضعون لعملية الديلزة الدموية او الغسيل الكلوي. يتطور هذا النقص في المغنيسيوم مبكرا اثناء دورة المرض و تزداد نسبته مع تدني فاعلية الكليتين.اهداف الدراسة: هدفت هذه الدراسة الى تحديد تاثير علاج ميثوكسي بولي اثيلين غليكول ايبوتين-بيتا على مستوى المغنيسيوم في مرضى الداء الكلوي بمراحله الاخيرة. المرضى والطرائق : ضمت دراسة الحالات والشواهد المقطع-عرضية هذه سبعين مريضا يعانون من الداء الكلوي بمراحله الاخيرة من الذين يتناولون علاج ميثوكسي بولي اثيلين غليكول ايبوتين-بيتا بالاضافة الى عشرين شخصا صحيحا.النتائج: سجل مستوى المغنيسيوم في الدم ارتفاعا ذو دلالة معنوية عالية ((p<0.01 عند القيمة القاعدية بالمقارنة مع الاشخاص الاصحاء في مجموعة السيطرة بسبب فقدان الكلى لوظيفتها لدى هؤلاء المرضى. ثم اعطيت جرعة علاج ميثوكسي بولي اثيلين غليكول ايبوتين-بيتا بعد ثلاثة اشهر من جرعة القيمة القاعدية فاظهرت انحدارا ذو دلالة معنوية في مستوى المغنيسيوم في المصل (p<0.05) لدى المرضى خلال الدراسة.الاستنتاجات : يمكن الاستنتاج بان الارتفاع النسبي في مستوى المغنيسيوم مرتبط بالداء الكلوي بمراحله الاخيرة و ان اعطاء علاج ميثوكسي بولي اثيلين غليكول ايبوتين-بيتا للمرضى يؤدي عادة الى هبوط معنوي في مستواه.

End stage renal disease --- M.PG.E-β --- Serum Magnesium --- مرض الداء الكلوي بمراحله الاخيرة --- M.PG.E-β --- المغنيسيوم في المصل.